Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer

Journal of the National Cancer Institute

Volumn 94, Issue 13, 2002, Pages 972-980

  Sandhu, Manjinder S ^a   Dunger, David B ^b   Giovannucci, Edward L ^c,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INSULIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BIOAVAILABILITY; BODY SIZE; CANCER CELL; CANCER INCIDENCE; CANCER RISK; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIET; DIET RESTRICTION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGY; FEMALE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; MALE; MIGRATION; MITOGENESIS; MOUSE; NONHUMAN; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; TWINS;

EID: 0037014743     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.13.972     Document Type: Review

References (111)

1. Food, nutrition and the prevention of cancer: A global perspective
2. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
3. Insulin and colon cancer
4. Serum C-peptide, IGF-I, IGFBPs, and colorectal cancer risk in women
5. The fourth Musketeer-from Alexandre Dumas to Claude Bernard
6. Prospective study of adult onset diabetes mellitus and risk of colorectal cancer in women
7. Colorectal cancer: Another complication of diabetes mellitus?
8. Glucose intolerance, plasma insulin levels, and colon adenomas in Japanese men
9. Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk?
10. Increased blood glucose and insulin, body size, and incident colorectal cancer
11. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ
12. Insulin resistance and promotion of aberrant crypt foci in the colon of rats fed on a high-fat diet
13. Insulin promotion of colon tumors in rats
14. Insulin injections promote the growth of aberrant crypt foci in the colon of rats
15. Aberrant crypt focus promotion and glucose intolerance: Correlation in the rat across diets differing in fat, n-3 fatty acids and energy
16. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26
17. Characterization of the synergistic effects of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell line
18. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
19. Insulin-like growth factors and their binding proteins: Biological functions
20. Possible mechanisms relating diet and risk of colon cancer
21. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and the risk of colorectal neoplasia in women
22. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF binding protein-3
23. Nutritional regulation of the insulin-like growth factors
24. The insulin-like growth factors
25. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
26. Insulin-like growth factors and cancer
27. The insulin growth factor I receptor: A key to tumour growth?
28. Insulin-like growth factors and binding proteins in colon cancer
29. Enhanced levels of insulin-like growth factor mRNA in human colon carcinomas and liposarcomas
30. Signal transduction mechanism of insulin and insulin-like growth factor-1
31. Normal growth and development in the absence of hepatic insulin-like growth factor I
32. Hormonal and nutritional regulation of IGF-I and its binding proteins
33. Quantitative genetic analyses of insulin-like growth factor-I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins
34. Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: Results from middle-aged and elderly monozygotic twins
35. Insulin-like growth factor binding proteins: New proteins, new functions
36. Colorectal neoplasia in acromegaly
37. Mortality and cancer incidence in acromegaly: A retrospective cohort study
38. Increased epithelial cell proliferation in the colon of patients with acromegaly
39. Insulin-like growth factor-I and the development of colorectal neoplasia in acromegaly
40. Growth hormone as a risk for premature mortality in healthy subjects: Data from the Paris prospective study
41. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
42. Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women
43. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity
44. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: Association with colorectal cancer in a cohort of Chinese men in Shanghai
45. Correspondence re: Giovannucci et al., a prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women
46. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: Evidence for in vivo biological activity
47. Expression of human insulin-like growth factor-binding protein-3 in transgenic mice
48. Presence of somatomedin receptors on primary human breast and colon carcinomas
49. Characterization of insulin-like growth factor I receptors in human colon cancer
50. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon
51. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha
52. Blockade of the insulin-like growth factor-I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF-II-mediated atocrine loop
53. The IGF-I receptor in cell growth, transformation and apoptosis
54. Differential regulation of signaling pathways for insulin and insulin-like growth factor I
55. Insulin-like growth factor-I receptor signal transduction: At the interface between physiology and cell biology
56. Insulin and insulin-like growth factor-I signal transduction requires p21ras
57. Hyperinsulinemia potentiates activation of p21Ras by growth factors
58. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I
59. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells
60. Dietary restriction reduces insulin-like growth factor-I levels, which modulates apoptosis, cell proliferation, and tumour progression in p53-deficient mice
61. Roles of insulin-like growth factor-I in mediating the anti-carcinogenic effects of caloric restriction
62. Stimulation of tumour growth by recombinant human insulin-like growth factor-I is dependent on the dose and the level of IGF-I receptor expression
63. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis
64. A polymorphism in the gene for IGF-I: Functional properties and risk for type 2 diabetes and myocardial infarction
65. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia
66. Effects of caloric and protein restriction on insulin-like growth factor-I and insulin-like growth factor binding proteins in children and adults
67. Hormonal responses to overfeeding
68. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting
69. Nutritional balance and stage of lactation affect responses of insulin, insulin-like growth factors I and II, and insulin-like growth factor-binding protein 2 to somatotropin administration in dairy cows
70. Insulin-like growth factor binding protein-1: Recent findings and new directions
71. The effect of oral glucose on serum free insulin-like growth factor-I and -II in healthy adults
72. Effect of insulin on the hepatic production of insulin-like growth factor binding protein-1, IGFBP-3, and IGF-I in IDDM
73. Changes in the circulating IGF system during short-term fasting and refeeding in rats
74. Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia caused by hyperinsulinism
75. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans
76. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects
77. Disturbances in the growth hormone-insulin-like growth factor axis in children and adolescents with different eating disorders
78. The effect of anorexia nervosa and refeeding on growth hormone binding protein, the insulin-like growth factors and their binding proteins
79. IGF-I and -II and binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: Correlation with metabolic control and height attainment
80. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone
81. Insulin-like growth factor binding proteins as glucoregulators
82. Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline
83. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children with exogenous obesity: Effect of short- and long-term weight reduction
84. Circulating levels of free insulin-like growth factors in obese subjects: The impact of type 2 diabetes
85. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): Evidence for a suppressive action of free rather than bound IGF-I
86. Changes in free insulin-like growth factor-I and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes
87. A genetic model for colorectal tumorigenesis
88. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis
89. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk
90. Role of the insulin-like growth factor family in cancer development and progression
91. Height, insulin-like growth factors and cancer risk
92. Insulin-like growth factor-I and binding protein-3 and risk of cancer
93. Energy balance and colon cancer-beyond physical activity
94. Energy balance and cancer: The role of insulin and insulin growth factor-I
95. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators
96. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men
97. Inhibition of tumour cell kinetics and serum IGF-I levels by octreotide in colorectal cancer patients
98. A randomized trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy
99. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma
100. Does recombinant human insulin-like growth factor have a role in the treatment of diabetes?
101. The growth hormone/insulin-like growth factor axis in critical illness
102. GH, IGF-I and binding proteins in altered nutritional states
103. Role of IGF-I in muscular atrophy of aging
104. Growth hormone and bone
105. Insulin-like growth factor-I: A key regulator of human cancer risk?
106. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans
107. IRS-2 coordinates IGF-I receptor-mediated beta-cell development and peripheral insulin signalling
108. Oncogenic kinase signalling
109. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice
110. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins